Bristol-Myers Squibb Stock Falls After Cancer Treatment Study Results Disappoint - Barron's

Bristol-Myers Squibb Stock Falls After Cancer Treatment Study Results Disappoint  Barron's

Bristol-Myers Squibb stock fell in after-hours trading on the back of disappointing data for a combination cancer treatment with its drugs Opdivo and Yervoy.



Comments

Popular posts from this blog

Stage 4 Lung Cancer Life Expectancy

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic ...

Free biotech stocks directory, pharma stocks, telemedicine stocks ...